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http://dxObjectives: We sought to evaluate whether there is variability in blood dexamethasone levels after a standard
1 mg/kg dose of dexamethasone administered before infant cardiopulmonary bypass. We hypothesized that
postoperative dexamethasone drug levels are highly variable, and that the infant stress response is related
inversely to the amount of dexamethasone measured in the blood.
Methods: Thirty-two infants (age, 365 days) received 1 mg/kg of dexamethasone before cardiopulmonary
bypass (CPB) initiation. Blood was analyzed for cortisol, adrenocorticotropin, and interleukin (IL)-6, IL-8,
and IL-10 levels after anesthesia induction, after CPB, after intensive care unit (ICU) arrival, and 4, 8, 12,
and 24 hours after surgery. Patients were grouped as high dexamethasone (15 mg/dL) or low dexamethasone
(<15 mg/dL) based on their level at ICU arrival.
Results: Dexamethasone levels varied significantly between the high (n¼ 22) and low (n¼ 10) dexamethasone
groups throughout the entire postoperative course and were correlated highly with cortisol response. Patients
with high dexamethasone levels had postoperative cortisol levels that were lower than their pre-CPB
baseline cortisol levels. Cortisol levels remained low throughout the first 24 postoperative hours even after
dexamethasone levels neared zero. There were no significant differences between groups in the duration of
mechanical ventilation or ICU length of stay.
Conclusions: Dexamethasone levels are highly variable at ICU arrival, despite standardized 1 mg/kg dosing
before CPB initiation. (J Thorac Cardiovasc Surg 2014;147:475-82)Corticosteroids remain a controversial but widely used
strategy for mediating the inflammatory/stress response
after infant cardiopulmonary bypass (CPB).1 Despite
decades of research investigating this question, the optimal
indication, drug type, dose, and timing for perioperative
corticosteroid administration remains unclear. As a result,
the approach to corticosteroid administration varies
significantly within and between cardiac surgical
programs.2 Surveys show that the younger the patient, the
more likely they are to receive pre-bypass corticosteroids
at a majority of US cardiac surgical centers.2 Infants
represent a subset of congenital heart disease (CHD)
patients who frequently present with complex CHD and
require surgical intervention early in life to optimize
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Mrisk for surgical mortality and require longer CPB times.
The heightened infant systemic inflammatory response to
CPB can lead to postoperative cardiac dysfunction and
hemodynamic lability.3,4 Pre-CPB corticosteroid adminis-
tration in this setting is believed to improve hemodynamic
stability, reduce fluid and vasopressor/inotrope require-
ments, and provide cardiac myocyte protection after
CPB.1,5,6
Many pediatric studies have attempted to advance our
understanding of the optimal corticosteroid approach for
mediating the infant perioperative cardiac surgical stress
response. Unfortunately, variability in study designs,
clinical practice, and patient selection has limited the ability
of these investigations to inform clinicians regarding best
practices for perioperative corticosteroid administration.
In general, these studies have generated more questions
than answers. Achieving consensus surrounding corticoste-
roid therapy requires a more detailed understanding of how
corticosteroids interact with the innate stress response.
We know that corticosteroid administration inhibits the
patient’s adrenal glands from releasing cortisol through a
negative feedback loop.7 However, the magnitude and
duration of this corticosteroid-induced suppression after
CPB is not well defined. Pharmacokinetic evaluations of
methylprednisolone and CPB would suggest that a standard
weight-based corticosteroid dose does not translate
consistently into equivalent drug levels in the blood for
every patient.8 Patient pharmacokinetics, hemodilution,rdiovascular Surgery c Volume 147, Number 1 475
Abbreviations and Acronyms
ACTH ¼ adrenocorticotropin
CHD ¼ congenital heart disease
CPB ¼ cardiopulmonary bypass
HCT ¼ hematocrit
ICU ¼ intensive care unit
IL ¼ interleukin
RACHES ¼ Risk Adjustment for Congenital Heart
Surgery
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Mvolume of modified ultrafiltration, and transfusion have the
potential to impact postoperative corticosteroid drug levels
and lead to variability in corticosteroid suppression of the
innate cortisol response. Past investigations seeking to
correlate cortisol levels with clinical outcomes have not
characterized this potential interaction between corticoste-
roid drug levels and the patient cortisol response.
We sought to evaluatewhether there is variability in blood
dexamethasone levels after a standard 1mg/kg dose of dexa-
methasone administered before infant cardiopulmonary
bypass. We hypothesized that postoperative dexamethasone
drug levels are highly variable, and that the infant stress
response is related inversely to the amount of dexametha-
sone measured in the blood. To test this theory we simulta-
neously measured blood levels of dexamethasone and
cortisol at critical time points during the perioperative
period for infants undergoing CPB for CHD surgery.
MATERIALS AND METHODS
Study Design and Patient Selection
We conducted a prospective trial of 32 infants (age, 365 days) who
presented to a single institution for congenital cardiac surgery from March
2009 to September 2010. Eligible participants were all infants who would
require CPB during their surgical procedure. Exclusion criteria included
prematurity (gestational age,<36 weeks), corticosteroid administration
within 24 hours preceding surgery, and preoperative mechanical
circulatory support. This study was approved by the Institutional Review
Board of the Mayo Clinic and parents provided signed informed consent.
Study Procedures and End Points
Blood was collected from study participants at 7 time points: (1) after
anesthesia induction, (2) after premodified ultrafiltration, (3) intensive care
unit (ICU) arrival, (4) postoperative hour 4, (5) postoperative hour 8, (6) post-
operative hour 12, and (7) postoperative hour 24. At each of the 7 time points,
blood was analyzed for the following levels: dexamethasone, cortisol,
adrenocorticotropin (ACTH), interleukin (IL)-6, IL-8, and IL-10.
Laboratory Analysis
ACTH levelwasmeasured using a solid-phase, sequential immunoassay on
theSiemens Immulite 2000automated immunoassay system (SiemensHealth-
care Diagnostics, Deerfield, Ill). Dexamethasone and cortisol were measured
by liquid chromatography–tandemmass spectrometry (ThermoFisher Scienti-
fic, Franklin, Mass, and Applied Biosystems-MDS Sciex, Foster City, Calif).
The IL-6, IL-8, and IL-10 assays were completed using a 20-plex
Procarta Cytokine Kit (Affymetrix, Santa Clara, Calif). All assays
were performed on a BioPlex 200 using BioPlex Manager 5.0 software476 The Journal of Thoracic and Cardiovascular Surg(Bio-Rad, Hercules, Calif). Lyophilized standards and controls also were
obtained from Affymetrix. Standards were hydrated in a plasma matrix
and serially diluted over a measuring range of 0.56 to 1215 pg/mL. Controls
were hydrated in the samematrix at concentrations of 175.0 and12.0 pg/mL.
All plasma ethylenediaminetetraacetic acid samples were run in duplicate,
at aminimum.Resultswere analyzedwith theBioPlex 5.0 software package
(Bio-Rad) using a 5-parameter logistics curve based on 8 standard points.
Corticosteroid Administration
Patients were treated according to the Mayo Clinic’s standard cortico-
steroid protocol. Each infant received a 0.5 mg/kg dose of dexamethasone
at anesthesia induction and CPB initiation to equal a total intraoperative
dexamethasone dose of 1 mg/kg.
Anesthesia Induction and Cardiopulmonary Bypass
Management
Anesthesia induction was achieved with fentanyl (25-50 mg/kg); midazo-
lam (0.1 mg/kg), a muscle relaxant; and titration of a volatile anesthetic agent.
The CPB extracorporeal circuit was primed with Plasmalyte (Baxter Health-
care Corp, Deerfield, Ill), 10 to 20 mEq sodium bicarbonate 8.5%, 0.5 g/kg
mannitol 12.5%, and 100mL of 25% albumin. No corticosteroids were given
in the pump prime. Washed packed red blood cells were added to the circuit
prime to achieve a hematocrit (HCT) of 25 to 30 upon initiation of CPB. In
addition, fresh-frozen plasma was added to the pump prime in all patients
weighing less than 5 kg and on select patients weighing between 5 and 10
kg. If the temperature was to remain above 32C, the HCT was kept above
25% and an alpha-stat oxygenator ventilation regimenwas used. Nonpulsatile
flow during CPB was maintained at 2.2 to 2.6 L/min/m2. Patient temperature
was monitored by a nasopharyngeal and urinary catheter probe for patients
weighingmore than4kgandonlybynasopharyngeal probe for patientsweigh-
ing less than 4 kg. For deep hypothermia procedures with circulatory arrest or
low-flow perfusion, a pH-stat cooling regimen was used during temperatures
lower than 32C and alpha-stat management was used upon rewarming.
Myocardial protection was accomplished with 20 to 30 mL/kg of high-
potassium cardioplegic solution, with additional cardioplegia given as needed
in a 10 to 15 mL/kg dose using a 1:4 blood crystalloid cardioplegic solution.
Upon rewarming, the HCTwas maintained at greater than 24% to 30%. All
patients received conventionalultrafiltrationduringCPB.Arteriovenousmodi-
fied ultrafiltration was performed for 15 to 20 minutes after separation from
CPB in all patients. All patients were admitted postoperatively to a dedicated
congenital cardiac intensive care unit and managed by a cardiac intensivist.
Patient Comparisons and Outcome Variables
Dexamethasone blood levels were compared at ICU arrival (time 3)
and subjects were classified as high dexamethasone (dexamethasone
level, 15 mg/dL) and low dexamethasone (dexamethasone level,
<15 mg/dL). The primary outcome measure compared between the
high and low dexamethasone groups was cortisol level at times 3, 4, and
5. Secondary outcome measures included the duration of mechanical
ventilation, ICU length of stay, ACTH levels, IL-6, IL-8, and IL-10 levels.
Statistical Analysis
Descriptive statistics for categoric variables are reported as frequencies
and percentages and continuous variables are reported as means standard
deviations with medians. Continuous variables measuring drug and blood
levels at different time points were compared between high dexamethasone
and low dexamethasone groups using 2-sample t test orWilcoxon rank sum
test where appropriate. All statistical tests were 2 sided, with the a level set
at 0.05 for statistical significance.
RESULTS
A total of 32 infants undergoing cardiac surgery
with CPB had blood samples collected and analyzed forery c January 2014
FIGURE 1. Distribution of dexamethasone levels at ICU arrival.
A scatterplot of the dexamethasone level for each patient as measured at
ICU arrival. The black line denotes a dexamethasone level of 15. Based
on the scatterplot distribution, patients were classified into 2 groups:
high dexamethasone level at ICU arrival of 15 or higher (n ¼ 10)
and low dexamethasone level at ICU arrival of less than 15 (n ¼ 22).
ICU, Intensive care unit; Dex, dexamethasone.
FIGURE 2. Dexamethasone and cortisol levels for the high dexametha-
sone versus low dexamethasone groups. Top: Mean dexamethasone levels
at each time point. Bottom: Mean cortisol responses over time for patients
with high (>15) versus low (15) dexamethasone levels. *Significant
differences between groups at the corresponding time point. ICU, Intensive
care unit; CPB, cardiopulmonary bypass; Dex, dexamethasone.
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Mdexamethasone, cortisol, and ACTH levels at 7 time points
during their perioperative course.
Dexamethasone drug levels measured in the blood at ICU
arrival were highly variable despite the standard 1 mg/kg
dose of dexamethasone administered to all patients before
CPB initiation. The dexamethasone level for each patient
at ICU arrival (time 3) was used to categorize the patients
into 2 groups: high dexamethasone (dexamethasone level,
15 mg/dL) versus low dexamethasone (dexamethasone
level, 15 mg/dL) to facilitate comparison of dexametha-
sone level with outcome measures. A dexamethasone
level of 15 was chosen as the cut-off point, based on the
observation that the majority of patients had dexamethasone
levels above or below this level, generating a natural
dividing line through the cohort (Figure 1). Ten patients
met the criteria for high dexamethasone and 22 patients
met the criteria for low dexamethasone, and these levels
were significantly different between the 2 groups at each
time point measured (Figure 2).
Patient characteristics are shown in Table 1. There were
no significant differences between groups with regard to
age, sex, CPB and aortic cross-clamp time, Risk Adjust-
ment for Congenital Heart Surgery (RACHS-1) category,
or classification of CHD as cyanotic or single-ventricle
physiology. Patients with high dexamethasone levels
trended toward lower inotrope scores at 24 hours but this
difference was not significant. Fifteen patients received
an additional dose of dexamethasone before extubation.
These patients were censored from the analysis at the
time they received these postoperative steroids to prevent
confounding of the dexamethasone, cortisol, ACTH, and
IL level measurements.
Both groups had similar cortisol levels at anesthesia
induction (predexamethasone) that decreased sharplyThe Journal of Thoracic and Caafter dexamethasone administration (time 2, end of
CPB). Cortisol levels diverged significantly at ICU arrival
between the high and low dexamethasone groups
(Figure 2). Patients in the high dexamethasone group
had lower cortisol levels (<5) throughout the postopera-
tive period. In fact, cortisol levels measured during the
first 24 postoperative hours were lower than the
baseline/pre-CPB cortisol levels and remained low even
after drug levels of dexamethasone had decreased to
near zero (Table 2). In contrast, the low dexamethasone
group showed an increase in cortisol at ICU arrival
compared with baseline/pre-CPB levels. These levels
climbed and peaked within 4 hours (time 4) after
surgery before returning to the pre-CPB/baseline levels.
ACTH levels followed a similar pattern to the cortisol
levels for each group. Patients with high dexamethasone
levels had a suppressed ACTH response throughout the
entire postoperative course (Table 2).
The fluctuations in perioperative cytokine responses were
very similar between the high and low dexamethasone
groups. However, the low dexamethasone group showed a
greater postoperative increase in the proinflammatoryrdiovascular Surgery c Volume 147, Number 1 477
TABLE 1. Patient characteristics
Characteristics
Low
dexamethasone
(n ¼ 22)
High
dexamethasone
(n ¼ 10)
P
value
Demographic variables
Age (d) 199  114 225  363 .83
Male, n (%) 10 (45%) 3 (30%) .66
RACHS-1 score
1-3, n 18 9 .95
4-6, n 4 1
Cyanotic congenital
heart disease, n (%)
15 (68%) 4 (40%) .26
Single ventricle
physiology, n (%)
3 (30%) 3 (14%) .54
CPB time (min) 104  44 90  35 .35
Cross-clamp time (min) 51  32 45  28 .63
Modified ultrafiltration (mL) 365  192 293  295 .49
Inotrope score
12 h 7.4 5.1 .12
24 h 7.2 4.6 .09
Mechanical ventilation
duration (d)
3.9  8.0 1.6  1.4 1.00
ICU length of stay (d) 12  14 11  11 .71
Data are reported as mean  standard deviation. RACHS-1, Risk Adjustment for
Congenital Heart Surgery; ICU, intensive care unit; CPB, cardiopulmonary bypass.
TABLE 3. Cytokine responses for times 1 though 7
Time periods n
Low
dexamethasone n
High
dexamethasone
P
value
IL-6
1 15 2.46  1.53 10 2.32  0.82 .697
2 15 19.15  32.76 10 9.20  9.69 .305
3 15 26.38  16.03 10 19.27  13.64 .256
4 15 21.65  9.95 9 14.87  11.61 .043
5 12 22.13  10.64 8 18.66  11.12 .335
6 12 22.12  10.39 6 13.99  6.37 .059
7 9 23.46  10.34 5 13.82  9.87 .116
IL-8
1 15 1.33  1.72 10 1.30  0.62 .127
2 15 5.40  4.91 10 5.93  6.59 .890
3 15 7.79  5.11 10 6.74  4.80 .637
4 15 5.69  4.24 9 5.12  3.10 1.000
5 12 5.43  3.69 8 4.41  2.35 .758
6 12 5.41  3.70 6 3.23  1.51 .098
7 9 7.57  7.49 5 2.96  1.05 .240
IL-10
1 15 1.58  3.61 10 0.95  0.78 .518
2 15 54.76  40.46 10 40.11  27.95 .296
3 15 46.64  27.87 10 44.77  32.13 .879
4 15 11.96  6.41 9 7.14  10.29 .015
5 12 7.46  6.23 8 3.77  2.22 .097
6 12 5.64  5.58 6 2.51  0.67 .174
7 9 13.87  30.87 5 1.78  1.49 .518
IL, Interleukin.
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in the postoperative anti-inflammatory IL-10 levels between
groups (Table 3).TABLE 2. Patient results for times 1 through 7
Time periods n
Low
dexamethasone n
High
dexamethasone
P
value
Dexamethasone
1 22 0.00  0.00 10 0.00  0.00 .980
2 22 17.92  7.27 10 32.48  12.35 .005
3 21 10.88  3.03 10 24.48  7.37 <.001
4 22 5.17  2.71 9 13.18  8.51 .002
5 17 2.25  1.43 8 9.90  7.98 .006
6 17 2.44  5.91 6 6.85  6.19 .009
7 11 1.05  2.78 5 2.31  2.27 .023
Cortisol
1 22 11.70  4.24 10 11.77  7.36 .978
2 22 6.35  4.65 10 6.58  5.35 .887
3 22 14.17  11.33 10 5.19  3.03 .016
4 22 14.07  14.52 9 5.07  4.79 .078
5 17 11.00  11.81 8 3.30  3.34 .180
6 17 10.42  13.45 6 2.08  1.54 .172
7 12 21.07  24.74 5 1.18  0.58 .018
ACTH
1 21 25.62  15.86 10 28.20  15.63 .674
2 22 12.48  13.06 10 13.13  17.57 .918
3 22 37.66  68.27 10 10.62  6.76 .080
4 22 16.25  17.84 9 6.79  3.12 .025
5 17 14.43  22.93 8 5.29  2.43 .123
6 17 10.92  14.09 6 5.80  2.97 .174
7 10 22.19  23.52 5 6.42  4.82 .069
ACTH, Adrenocorticotropin.
478 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
We showed that a standardized 1 mg/kg dose of
dexamethasone administered before CPB, results in
postoperative dexamethasone blood levels that are highly
variable. Infants could be divided into high and low
dexamethasone responders based on their drug levels at
ICU arrival. These levels were highly correlated with the
amount of cortisol suppression observed during the first
24 postoperative hours. Patients with higher postoperative
blood levels of dexamethasone showed lower cortisol
levels throughout the entire postoperative period. For
these patients, cortisol suppression persisted even after
dexamethasone levels were near zero. The variations in
cortisol response observed between groups (high dexameth-
asone vs low dexamethasone) was not accounted for by
differences in CPB time, surgical case complexity, aortic
cross-clamp time, modified ultrafiltration volume, type of
congenital heart disease, or the magnitude of the inflamma-
tory response.
Studies investigating the infant post-CPB stress response
have been unable to identify consistent correlations
between cortisol level and clinical outcomes to define an
appropriate cortisol/stress response. This knowledge gap
remains at the heart of the perioperative corticosteroid
debate and hinders the design and interpretation of past
and future research investigations. The inconsistency andery c January 2014
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Mwide ranges observed in cortisol levels between and within
studies is significant. This variability partially may be
explained by our findings that postoperative drug levels
vary despite standardized intraoperative corticosteroid
administration. Our data would suggest that low cortisol
levels actually may be the result of higher blood levels of
corticosteroid rather than underlying adrenal suppression.
In this scenario, patients with true underlying adrenal
insufficiency and low cortisol levels would be indistinguish-
able from infants with low cortisol levels secondary to
corticosteroid-induced suppression.
Our findings suggest that standard weight-based dosing
of corticosteroids may result in the inflammatory/stress
response of infants being oversuppressed in some and
undersuppressed in others. This leads to the ultimate
question that has yet to be answered, ‘‘What is optimal
suppression of the post-CPB inflammatory/stress
response?’’ The CPB-generated inflammatory/stress
response has been well demonstrated, and the younger the
age of the child, the more robust the response.9 This
inflammatory/stress response has been associated with a
variety of poor outcomes. Higher levels of the inflammatory
markers IL-6 and IL-8 correlate with increased 24-hour
lactates and longer ICU lengths of stay for neonates after
congenital cardiac surgery.10 Similarly, there are some
data to suggest that a heightened stress response after
cardiac surgery may be maladaptive. Mackie et al11
observed that neonates with higher postoperative cortisol
levels had increased atrial filling pressures and a lower
cardiac index over the first 48 postoperative hours. Wald
et al12 found that patients with larger increases in cortisol
after a postoperative cosyntropin stimulation test had higher
inotrope and fluid requirements and increased ventilator
time and ICU length of stay. Further evidence for the value
of corticosteroid suppression of the inflammatory/stress
response comes from 3 small randomized clinical trials
showing that intraoperative dexamethasone was associated
with lower postoperative troponin when compared with
placebo.1,5,13
In contrast, recent large-scale investigations of the
Pediatric Health Information Systems Database have
raised concerns that, at least for some patients, the risks
of corticosteroids may outweigh the benefits. Two separate
analyses using the Pediatric Health Information Systems
Database to evaluate pre-CPB corticosteroid use in
neonates and 0 to 18 year olds failed to find any clinical
benefit. In fact, patients with lower surgical risk according
to their RACHS-1 classification, experienced higher rates
of infection, insulin use, and longer hospital lengths of
stay.14,15 These findings, combined with our observation
that standard weight-based dosing produces widely variable
blood corticosteroid levels requires consideration of a more
individualized approach to post-CPB immunomodulation.
Patients in RACHS-1 categories 1 through 3 are often olderThe Journal of Thoracic and Caand require shorter CPB times, which should translate into a
less robust inflammatory/stress response. This subset of
patients may not require steroids to achieve optimal
postoperative recovery. On the other hand, surgical cases
in RACHS-1 categories 4 through 6 are significantly more
complex and are associated with a higher risk for morbidity
and mortality. Dexamethasone under-responders (ie, the
low dexamethasone group) in these categories may experi-
ence a suboptimal suppression of their inflammatory/stress
response that goes unrecognized using the current
weight-based approach to corticosteroid administration.
A third consideration is the possibility that, for some
children, intraoperative corticosteroids actually generate
an iatrogenic transient adrenal insufficiency. Our study
showed that for high dexamethasone responders (ie, those
patients with high postoperative dexamethasone levels),
cortisol and ACTH levels remained suppressed long
after blood levels of dexamethasone had decreased.
Dexamethasone levels were near zero within 24 hours of
ICU arrival (time 7) and yet cortisol and ACTH levels
continued to trend downward for the high dexamethasone
group. This time period when the innate stress response
remained suppressed but exogenous corticosteroids were
no longer being administered could place the patient at
increased risk for lability and poor outcome during the acute
postoperative period.
The delayed recovery of the cortisol response observed in
our study was consistent with the genomic actions of
glucocorticoids. Glucocorticoids exert their effects through
both genomic and nongenomic pathways. Nongenomic
effects are rapid in onset and offset, acting directly at
glucocorticoid receptors or through non–receptor-mediated
pathways. Genomic effects involve glucocorticoid-receptor
binding that initiates downstream alterations in transcrip-
tion and translation to induce anti-inflammatory cytokine
production (eg, IL-10), suppress proinflammatory cytokines
(eg, IL-6, IL-8), and impact cortisol release through
interactions with the hypothalamic-pituitary-adrenal axis.
Genomic mechanisms of action are slower in onset and
offset, and likely explain the persistence of low cortisol
levels even after dexamethasone is cleared from the blood
in the high dexamethasone group.7 Whether or not this
delayed recovery in the cortisol response creates a
clinically significant adrenal insufficiency after pre-CPB
dexamethasone administration requires further investiga-
tion in a larger population of patients.
Although this was the first study to our knowledge to
measure dexamethasone levels after infant CPB, previous
investigations have shown a similar variation in drug levels
after intraoperative methylprednisolone (MP) administra-
tion.8 Evaluations of adult glucocorticoid pharmacokinetics
and pharmacodynamics have identified a variety of factors
that impact drug clearance and bioavailability including
age, sex, albumin levels, and chronic hepatic insufficiency.7rdiovascular Surgery c Volume 147, Number 1 479
Perioperative Management Crow et al
P
MThe impact of these factors and CPB-related variables on
dexamethasone potency and clearance in the infant CHD
population are unknown. Metabolism and clearance of
dexamethasone is accomplished primarily through the
liver. Differences in cytochrome P-450–mediated drug
metabolism have been observed within populations of
healthy children as well as children with sepsis and multi-
organ failure.16,17 An increase in the proinflammatory
cytokine IL-6 is associated with a reduction in cytochrome
P-450–mediated metabolism for a variety of drugs
including dexamethasone.16,18 Age, co-administration of
other cytochrome P-450–metabolized medications, and
genetic factors all can impact drug metabolism and
clearance. Our study population was too small to
evaluate the potential contribution of these characteristics.
Ideally, future investigations will seek to identify patient-
and drug-related characteristics that can facilitate an
individualized approach to perioperative corticosteroid
administration for infant CPB.
The ultimate challenge is to establish an optimal balance
between suppression and augmentation of the inflamma-
tory/stress response. The ideal dexamethasone dose will
mediate harmful effects of the inflammatory response,
including vasodilation, capillary leak, and cardiac myocyte
injury, and simultaneously avoid suppression of adaptive
host mechanisms such as cortisol release and immunomo-
dulation that is protective against infection. In our study,
inflammatory cytokines, IL-6, and IL-8 levels were very
similar between groups, despite significant differences in
dexamethasone levels. These findings suggest that low
dexamethasone levels (<15 mg/dL) may be sufficient to
mediate the inflammatory response without inducing
prolonged suppression of the patient’s innate stress
response. Future investigations must seek to identify
patient characteristics that predict maladaptive post-CPB
inflammatory responses and impact corticosteroid
pharmacokinetics/pharmacodynamics. This knowledge
will facilitate an individualized approach that addresses
patient-specific CPB response and pharmacodynamics/
pharmacokinetics to inform corticosteroid selection, dose,
timing, and duration that will balance the risk/benefit ratio
for each patient.
There were several limitations to this study that require
further consideration. First, the small sample size in our
study precluded rigorous statistical evaluation of all the
potential factors that may impact postoperative dexametha-
sone drug levels. Measurement of these levels in a larger
patient population will be required to evaluate the impact
of factors such as age, weight, blood loss, transfusion,
and patient-specific pharmacokinetics on postoperative
corticosteroid drug levels. A second potential limitation
was the single-center nature of this investigation. Although
the anesthetic, cardiopulmonary bypass, and corticosteroid
approach for patients within our center was quite consistent,480 The Journal of Thoracic and Cardiovascular Surgpractice patterns can be highly variable between
institutions. We are currently in the process of addressing
these limitations with a follow-up study that measures
dexamethasone and cortisol levels surrounding infant
CPB at 2 independent institutions. Finally, 15 patients in
our study received corticosteroids during the postoperative
period just before extubation. Patients were censored
from the analysis once they received postoperative
corticosteroids to ensure that the observed variability in
drug levels was not affected by the additional corticosteroid
administration. However, these patients were still included
in the comparison of the clinical outcomes of mechanical
ventilation and ICU length of stay. Despite these
limitations, our study was the first to show that postopera-
tive dexamethasone drug levels are highly variable. These
findings highlight drug levels as an additional factor that
must be considered when evaluating the implications of
this highly prevalent clinical practice.
In conclusion, we showed that a standardized 1 mg/kg
dose of dexamethasone given to infants before CPB
initiation generates significantly different blood levels of
dexamethasone at ICU arrival. These dexamethasone levels
are highly correlated with the magnitude of the postopera-
tive cortisol/stress response. Higher dexamethasone levels
are associated with suppression of the postoperative cortisol
response that persists after dexamethasone blood levels
decrease, potentially generating a period of iatrogenic
adrenal insufficiency that could impact postoperative
stability. These findings establish that corticosteroid blood
levels are an important variable to consider when evaluating
the role of perioperative corticosteroids for mediating the
infant CPB-induced stress/inflammatory response.References
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MDiscussion
Dr Olaf Reinhartz (Stanford, Calif). Thank you. Dr Crow, you
and your group are to be commended for trying to shed light on a
subject that still remains quite nebulous to us. The benefits of
perioperative steroids for complex congenital repairs are still
unclear, and, as of late, as you mentioned, there is even evidence
that steroids might actually be harmful at least in some patients.
Practice between institutions varies as widely as one would
imagine.
Your study is carried out well and has 3 important findings.
Number one, blood drug levels despite consistent drug dosage
are highly variable, and this variation is not easily explained by
patient factors like age, complexity of the procedure, etcetera.
Secondly, expectedly and logically higher drug levels lead to
more and longer adrenal suppression. And, third, cytokine levels
are not different between high and low drug levels in your
2 groups.
I have 2 questions for you. I will ask them one at a time. The first
one relates to the large drug level variability. I cannot come up with
an explanation why there would be 2 distinct groups as you are
describing them, high versus low dexamethasone levels in your
study. Did you just arbitrarily categorize these patients into 2
groups? I did not see a scattergram to facilitate analysis. Or, do
you really think there are 2 distinct patient populations and you
just have not found out yet what distinguishes them?
Dr Crow. Yes, it is an excellent question. We did not have 2
distinct groups. They were scattered around this 15 mg/dL mark
that I chose, and I just tried to find a point that looked like most
of the group fell above or below in order to make some
comparisons.The Journal of Thoracic and CaThere is a wide range of variability, but there does appear to be
significant differences between the 2 groups. If you divide on that
15 mark, the groups are significantly different between their levels
at each point in time.
We do have some studies in methylprednisolone in adults that
demonstrate that there is a large variety of components that could
contribute to this. And there have even been some studies by Joe
Carcillo that show that even in healthy children, we will have
differences in drug metabolism.
So inflammatory markers also play into drug metabolism,
and IL-6 specifically has been shown to decrease clearance
with the cytochrome P450 system, which is utilized to clear
dexamethasone.
We did not find a difference in IL-6 levels in our population that
would have explained that, but I think it just highlights that there
are many, many questions that still need to be investigated to try
to figure out why there is such discrepant levels in these patients.
Dr Reinhartz. Secondly, you and others before you have
proposed larger prospective multicenter trials around this topic.
How would you design these trials? What should the treatment
arms be, particularly in light of the more recent data that you
mentioned questioning the benefit of perioperative steroids
entirely?
Dr Crow. I love this question because I think it is really where
the field needs to go now. I think especially with the latest large
studies showing potential negative outcomes of corticosteroid
treatment. As a result, the clinical equipoise around the practice
has grown even in the last 5 years. I am amazed at how much
more willing people are to consider not giving corticosteroids
intraoperatively. There are now centers that do not give
corticosteroids and centers that do give.
So I do think that while we still have some challenges to get
people to buy into a randomized clinical trial, which would be
the gold standard, there is a possibility to design a study where
we take different centers that have different steroid practices,
measure these blood levels in those patients in a larger sample,
and try to figure out is the best strategy. Are there drug levels
that can suppress the components we need to suppress, and will
not suppress things like the immune system that are needed to
prevent infection?
We have just completed analysis on samples from an additional
center, and so we will have the opportunity to look at patients at 2
different centers and have preliminary data to pursue that kind of
multicenter investigation. In this scenario, people could still use
their standard practices, but we could monitor how those practices
translate into postoperative inflammatory/stress responses and try
to draw some conclusions from that information.
Dr James S. Tweddell (Milwaukee, Wis). That was a really
very interesting study and an excellent presentation. I have just a
couple of questions.
How far in advance of skin incision or initiation of bypass were
the steroids given?
Dr Crow. Steroids are usually given immediately after the
patients are asleep and then right before the bypass prime.
Sowe had about an hour time period. I actually went and looked
at each of them individually, and for all the patients they got
0.5 mg/kg of dexamethasone right after induction and then another
0.5 mg/kg right before bypass was starting. And that was therdiovascular Surgery c Volume 147, Number 1 481
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Mstandard protocol for all the patients. This time period was about
an hour for each patient.
Dr Tweddell.Did you look at any variability in that interval be-
tween the first dose and the second dose? Did that have an impact?
Dr Crow. So we actually did not have very much variability.
Outside of about 20 minutes, the intervals between those steroids
were very similar. You could also question variability in the time
between steroid administration and ICU arrival, since we use the
level at ICU arrival to divide the patients into 2 groups. There
was variability between when bypass started and when it would
have finished, and when the patient arrived to the ICU. In an
attempt to control for this variability, we compared bypass times
between groups. That is sort of a surrogate marker of how long
the operative time is for these patients. There were no significant
differences in bypass time between groups.
But, again, this is another area where it would be nice to have a
larger patient population where you could look a little more
discretely at some of those variables. Twenty minutes might end
up being significant if you had enough patients to look at it in.
Dr Tweddell. Is there any potential to go back and look at the
ACTH levels in these patients?
Dr Crow. Yes. I can actually show it to you right now.
Dr Tweddell. I’m glad I asked a question you are prepared for.
Dr Crow. Well, I did not have time to put it in. Otherwise,
I would have shown you that, too.
But the ACTH levels were quite similar to the cortisol levels,
and they were similarly suppressed, as you can see, in that high
dexamethasone group.482 The Journal of Thoracic and Cardiovascular SurgSo, it looks like we suppressed the entire axis. And, in fact,
dexamethasone is a more potent suppressor of the stress response
than your innate cortisol levels. So when I show that negative
feedback loop, our cortisol does not suppress the hypothalamus
pituitary as much as dexamethasone does.
So, we are really playing with a pretty powerful mediator. And
we know the genomic effects of dexamethasone work through
transcription and translation and will actually produce a much
more prolonged effect on adrenal suppression even after the blood
levels have cleared.
So, I think it is very interesting that we have that time period
where we are no longer supplementing. Cortisol levels are low
and ACTH levels are low, lower even than when the patient first
came to surgery.
I am looking forward to looking closer at that 8- and 24-hour
time period and beyond to see if we can actually pick out patients
that are more labile during that time or kind of seem to be doing
okay and then get worse. Is that part of the problem—that we
have created this iatrogenic adrenal insufficiency?
Dr Lyle D. Joyce (Rochester, Minn). Dr Crow, I assume you
would be happy to have any centers here that are interested in
joining you to contact you, right?
Dr Crow. Yes. That would be great.
Dr Joyce. Because, as you say, there is variability across the
country, and it would be nice to sort that out.
Dr Crow. Yes. The key to answering this question will
definitely be multicenter evaluation of what we are already
doing.ery c January 2014
